A. Goldsmith Mark's Insider Trades & SAST Disclosures
A. Goldsmith Mark's most recent trade in Revolution Medicines Inc was a trade of 11,738 Common Stock done at an average price of $39.0 . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern A. Goldsmith Mark.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.04 per share. | 17 Mar 2025 | 11,738 | 441,564 (0%) | 0% | 39.0 | 458,255 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 341,100 | 0 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 97,400 | 453,302 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Goldsmith A. Mark | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 30,846 | 0 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 18 Dec 2024 | 30,846 | 355,902 (0%) | 0% | 0.5 | 15,115 | Common Stock |
| Revolution Medicines Inc | Goldsmith A. Mark | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.40 per share. | 16 Dec 2024 | 11,714 | 325,056 (0%) | 0% | 45.4 | 531,860 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 50,900 | 181,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.56 per share. | 01 Nov 2024 | 50,900 | 300,170 (0%) | 0% | 55.6 | 2,827,821 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Nov 2024 | 50,900 | 351,070 (0%) | 0% | 4.1 | 208,181 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 36,600 | 30,846 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 01 Nov 2024 | 36,600 | 336,770 (0%) | 0% | 0.5 | 17,934 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Nov 2024 | 9,100 | 309,270 (0%) | 0% | 4.1 | 37,219 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,100 | 232,129 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.02 per share. | 01 Nov 2024 | 9,100 | 300,170 (0%) | 0% | 55.0 | 500,714 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.02 per share. | 01 Nov 2024 | 5,000 | 20,424 (0%) | 0% | 55.0 | 275,105 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.03 per share. | 01 Nov 2024 | 5,000 | 20,424 (0%) | 0% | 55.0 | 275,134 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 11 Oct 2024 | 30,000 | 330,170 (0%) | 0% | 4.1 | 122,700 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 50.36 per share. | 11 Oct 2024 | 30,000 | 300,170 (0%) | 0% | 50.4 | 1,510,773 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 30,000 | 241,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Oct 2024 | 10,000 | 310,170 (0%) | 0% | 4.1 | 40,900 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 10,000 | 271,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 44.80 per share. | 01 Oct 2024 | 7,978 | 302,192 (0%) | 0% | 44.8 | 357,409 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.46 per share. | 01 Oct 2024 | 2,022 | 300,170 (0%) | 0% | 45.5 | 91,913 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 44.19 per share. | 16 Sep 2024 | 11,715 | 300,170 (0%) | 0% | 44.2 | 517,631 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Aug 2024 | 10,000 | 321,885 (0%) | 0% | 4.1 | 40,900 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 281,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.60 per share. | 01 Aug 2024 | 6,783 | 315,102 (0%) | 0% | 45.6 | 309,308 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 46.48 per share. | 01 Aug 2024 | 3,217 | 311,885 (0%) | 0% | 46.5 | 149,519 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 25,000 | 291,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.05 per share. | 12 Jul 2024 | 25,000 | 311,885 (0%) | 0% | 45.0 | 1,126,205 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 12 Jul 2024 | 25,000 | 336,885 (0%) | 0% | 4.1 | 102,250 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 12 Jul 2024 | 5,000 | 25,424 (0%) | 0% | 45.0 | 225,059 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 12 Jul 2024 | 5,000 | 25,424 (0%) | 0% | 45.0 | 225,058 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 37.39 per share. | 17 Jun 2024 | 11,950 | 311,885 (0%) | 0% | 37.4 | 446,770 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 03 Jun 2024 | 7,500 | 329,822 (0%) | 0% | 4.1 | 30,675 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 7,500 | 316,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.99 per share. | 03 Jun 2024 | 5,699 | 323,223 (0%) | 0% | 40.0 | 227,880 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 40.93 per share. | 03 Jun 2024 | 901 | 322,322 (0%) | 0% | 40.9 | 36,881 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.09 per share. | 03 Jun 2024 | 900 | 328,922 (0%) | 0% | 39.1 | 35,182 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 35.48 per share. | 10 Apr 2024 | 7,500 | 452,879 (0%) | 0% | 35.5 | 266,122 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 35.33 per share. | 10 Apr 2024 | 5,000 | 30,424 (0%) | 0% | 35.3 | 176,659 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 35.34 per share. | 10 Apr 2024 | 5,000 | 30,424 (0%) | 0% | 35.3 | 176,687 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 18 Mar 2024 | 5,788 | 460,379 (0%) | 0% | 31.6 | 182,804 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 314,000 | 314,000 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 90,000 | 466,167 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | A. Goldsmith Mark | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 18 Dec 2023 | 8,165 | 376,167 (0%) | 0% | 25.9 | 211,488 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 363,000 | 363,000 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 104,000 | 355,872 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 22 Feb 2023 | 45,000 | 251,872 (0%) | 0% | 0.5 | 22,050 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 45,000 | 102,446 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 10,000 | 147,446 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 11 Aug 2022 | 10,000 | 206,872 (0%) | 0% | 0.5 | 4,900 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 10,336 | 157,446 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 09 Aug 2022 | 10,336 | 196,872 (0%) | 0% | 0.5 | 5,065 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 18.61 per share. | 17 Mar 2022 | 1,023 | 185,599 (0%) | 0% | 18.6 | 19,042 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 363,000 | 363,000 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 104,000 | 186,622 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 37,721 | 167,782 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 06 Dec 2021 | 37,721 | 84,193 (0%) | 0% | 0.5 | 18,483 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 17 Sep 2021 | 1,531 | 46,472 (0%) | 0% | 30.0 | 45,961 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.13 per share. | 17 Jun 2021 | 1,465 | 48,023 (0%) | 0% | 34.1 | 50,000 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 33.50 per share. | 17 Jun 2021 | 20 | 48,003 (0%) | 0% | 33.5 | 670 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 169,000 | 169,000 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 48,000 | 48,744 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 01 Mar 2021 | 5,000 | 5,744 (0%) | 0% | 1.1 | 5,600 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 5,000 | 58,486 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 46.00 per share. | 01 Mar 2021 | 5,000 | 744 (0%) | 0% | 46.0 | 229,981 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 05 Feb 2021 | 15,000 | 744 (0%) | 0% | 55 | 825,000 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 15,000 | 63,486 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 05 Feb 2021 | 15,000 | 15,744 (0%) | 0% | 1.1 | 16,800 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Feb 2021 | 246,604 | 247,093 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 5,000 | 78,486 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 02 Feb 2021 | 5,000 | 5,744 (0%) | 0% | 1.1 | 5,600 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.26 per share. | 02 Feb 2021 | 4,200 | 1,544 (0%) | 0% | 45.3 | 190,096 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 46.26 per share. | 02 Feb 2021 | 800 | 744 (0%) | 0% | 46.3 | 37,005 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.40 per share. | 28 Sep 2020 | 42,578 | 0 (0%) | 0% | 34.4 | 1,464,854 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 42,548 | 520,841 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 28 Sep 2020 | 42,548 | 42,548 (0%) | 0% | 4.7 | 201,252 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.14 per share. | 28 Sep 2020 | 30,523 | 0 (0%) | 0% | 34.1 | 1,041,918 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.08 per share. | 28 Sep 2020 | 21,088 | 73,191 (0%) | 0% | 34.1 | 718,652 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 20,076 | 563,389 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 28 Sep 2020 | 20,076 | 30,523 (0%) | 0% | 4.7 | 94,959 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 10,447 | 331,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 28 Sep 2020 | 10,447 | 10,447 (0%) | 0% | 4.1 | 42,728 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 10,132 | 341,676 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.11 per share. | 28 Sep 2020 | 10,132 | 0 (0%) | 0% | 34.1 | 345,567 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 28 Sep 2020 | 10,132 | 10,132 (0%) | 0% | 4.1 | 41,440 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.08 per share. | 28 Sep 2020 | 7,500 | 94,279 (0%) | 0% | 34.1 | 255,605 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.12 per share. | 28 Sep 2020 | 1,312 | 71,879 (0%) | 0% | 34.1 | 44,762 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 30 | 83,486 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 28 Sep 2020 | 30 | 42,578 (0%) | 0% | 1.1 | 34 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 21 Sep 2020 | 29,903 | 0 (0%) | 0% | 33.0 | 986,850 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 21 Sep 2020 | 29,903 | 29,903 (0%) | 0% | 4.1 | 122,303 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 29,903 | 362,005 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 21 Sep 2020 | 11,459 | 102,420 (0%) | 0% | 33.0 | 378,173 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 33.15 per share. | 21 Sep 2020 | 10,097 | 0 (0%) | 0% | 33.1 | 334,713 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 21 Sep 2020 | 10,097 | 10,097 (0%) | 0% | 4.1 | 41,297 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 10,097 | 351,908 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 21 Sep 2020 | 541 | 101,879 (0%) | 0% | 33 | 17,853 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 21 Sep 2020 | 100 | 101,779 (0%) | 0% | 34.0 | 3,402 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 34.01 per share. | 21 Sep 2020 | 100 | 0 (0%) | 0% | 34.0 | 3,401 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges